162 mg of Aspirin for Prevention of Preeclampsia

• Status: Recruiting
• Trial end date: 2022-06-09
• Target enrollment: 0
• Participant gender: Female

Summary

This is a study to assess if 162 mg of aspirin will decrease rates of preeclampsia in pregnant patients compared to 81 mg of aspirin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Methodist Medical Center of Illinois
• Collaborators: UICOM Peoria Family Medicine Residency; University of Illinois College of Medicine at Peoria
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Any pregnant patient at Peoria FMC

• Hx of pre-eclampsia

• Multifetal gestation

• Chronic hypertension

• Type 1 or 2 diabetes

• Autoimmune disease

• Renal disease

• Nulliparity

• Obesity

• Family Hx of pre-eclampsia

• Sociodemographic characteristics

• Age >= 35 years of age

• Personal history factors (LBW, SGA, > 10-year pregnancy interval, adverse pregnancy outcomes

Exclusion Criteria:

• At high risk of side effects from ASA therapy

• Hx of hemorrhagic stroke

• Hx of GI bleed, G6PD

• Liver disease

• NSAID or Salicylate allergy)

• Patients confirmed to be not compliant with therapy